Biogen Inc. is a large American multinational biotechnology company located in Cambridge, Massachusetts; it mainly focuses on the discovery, development, and delivery of procedures for the treatment of hematologic, neurodegenerative, and autoimmune diseases to cure patients in worldwide.
In the year of 2014, Biogen Launched Eloctate in the U.S. at a low price than the current and vastly used drug Advate.
Novo Nordisk proclaimed the acquisition of their new production plant in New Hampshire. The addition has done, as an initiative to safeguard the production capability for the company’s hemophilia products was endure over the forecast period.
To know more, read @ https://www.marketdataforecast.com/market-reports/hemophilia-management-Market-310/
Market Data Forecast published a report named Hemophilia Management Market. Hemophilia Management Market worth was USD 5.72 billion in 2019, and it was estimated to be reached at a CAGR of 1.72%, to reach USD 6.8 billion by 2024.
Report segmented as:
- Hemophilia A
- Hemophilia B
- Other drugs
More costs related with the hemophilia treatment bounds the adoption by end-user and hinders the growth of this market. Many practical and advanced treatments are available in the U.S., but they may need a lifelong infusion of expensive drugs they manufactured through recombinant biotechnology (or) from human plasma.
Based on geography, the market divided under many countries namely, Asia-Pacific, North America, Africa, the Middle East, and Latin America and Europe. Europe has led the Hemophilia Management Market, and Asia-pacific estimated to reach the highest rate.
Key Market Players:
- Bayer Pharma AG
- Baxter International Inc.
- Grifols International SA.
- Novo Nordisk A/S
- CSL Behring
- Biogen Idec, Inc.
- CSL Behring
- Ferring B.V.
- Chugai Pharmaceutical Co.
- Hospira, Inc.
- Genentech, Inc.
- Octapharma AG
- Novo Nordisk
- Pfizer, Inc.
- Sanofi SA
- Shire Plc.
- Swedish Orphan Biovitrum AB
View a sample and decide @ https://www.marketdataforecast.com/market-reports/hemophilia-management-market-310/request-sample
The Scope of the report:
The report offers a comprehensive examination of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along with this, the factors influential in influencing the market dynamics and trends discussed in detail at the product level. Further, the performance of the market at the regional and country-level had assessed, and the prospects with huge growth potential identified and debated.
The key players in the industry are profiled giving insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry had provided. The report also provides a broad outlook of the current market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.
Market Data Forecast is a firm working in the areas of market research, business intelligence and research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.
For more information:
Sales Manager at Market Data Forecast
Email: [email protected]
The post Hemophilia Management Market – Biogen launched Eloctate in the U.S. appeared first on Market Data Forecast Blog.